Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
BMC Dev Biol
2011 Nov 23;11:71. doi: 10.1186/1471-213X-11-71.
Show Gene links
Show Anatomy links
Maternal topoisomerase II alpha, not topoisomerase II beta, enables embryonic development of zebrafish top2a-/- mutants.
Sapetto-Rebow B
,
McLoughlin SC
,
O'Shea LC
,
O'Leary O
,
Willer JR
,
Alvarez Y
,
Collery R
,
O'Sullivan J
,
Van Eeden F
,
Hensey C
,
Kennedy BN
.
???displayArticle.abstract???
BACKGROUND: Genetic alterations in human topoisomerase II alpha (TOP2A) are linked to cancer susceptibility. TOP2A decatenates chromosomes and thus is necessary for multiple aspects of cell division including DNA replication, chromosome condensation and segregation. Topoisomerase II alpha is also required for embryonic development in mammals, as mouse Top2a knockouts result in embryonic lethality as early as the 4-8 cell stage. The purpose of this study was to determine whether the extended developmental capability of zebrafish top2a mutants arises from maternal expression of top2a or compensation from its top2b paralogue.
RESULTS: Here, we describe bloody minded (blm), a novel mutant of zebrafish top2a. In contrast to mouse Top2a nulls, zebrafish top2a mutants survive to larval stages (4-5 day post fertilization). Developmental analyses demonstrate abundant expression of maternal top2a but not top2b. Inhibition or poisoning of maternal topoisomerase II delays embryonic development by extending the cell cycle M-phase. Zygotic top2a and top2b are co-expressed in the zebrafish CNS, but endogenous or ectopic top2b RNA appear unable to prevent the blm phenotype.
CONCLUSIONS: We conclude that maternal top2a enables zebrafish development before the mid-zygotic transition (MZT) and that zebrafish top2a and top2b are not functionally redundant during development after activation of the zygotic genome.
Figure 1. Phenotype of the zebrafish bloody minded (blm) mutant. A) Mutants can be first recognized at ~27 hpf when signs of malformation in the head are visible (red arrows). At 2 and 3 dpf, eyes are much smaller and the tail is bent dorsally. B) Plastic sections through the eye reveal apoptotic cells in the retina (red arrow) and in the brain at 27 hpf. There is no proper lamination of the retina and necrosis proceeds. Abbreviations: hpf - hours post fertilisation, dpf - days post fertilisation, R - retina, L - lens, PhL - photoreceptor layer, INL - inner nuclear layer, IPL - inner plexiform layer, GCL - ganglion cells layer.
Figure 2. blm arises from a mutation in the top2a gene. A) Mapping of blm reveals that the gene is located on chromosome 12. B) top2a was selected as a candidate gene and sequencing of mutant cDNA shows a point mutation (AâT) in Lys residue 335 resulting in a premature stop codon. C) A schematic of wildtype Top2a protein and the truncated proteins in hi3635, blm and can4 mutants D) Complementation assay performed to confirm that blm is top2a mutation. blm heterozygotes were crossed to hi3635 carriers and the resulting hybrid offspring present with blm phenotype.
Figure 3. top2a mutants exhibit defects in cell cycle progression. A) Flow cytometry analysis of larvae at 27 hpf (red plot - wt, blue - blm) reveals an increased fraction of cells in G2/M phase in blm mutants. B) Representative Z-series projections showing that the total number of mitotic cells (stained with PH3 antibody - red) is lower in the eye of 27 hpf blm mutants (n = 58) than in wild type larvae (n = 70). C) The percentage of mitotic cells (PH3 positive) relative to the total number of DAPI stained cell nuclei is significantly (p = 0.036) higher in blm mutants compared to wild type as assessed from n ⥠23 sections through the head and spinal cord of the N = 5 mutant and wild type larvae. D) Real time PCR of cell cycle markers p21-like (G1 phase) and ccnb1 (G2/M phase) in wildtype and blm larvae at 27 hpf shows no significant difference in expression levels (p = 0.21 and 0.38, respectively). Expression of atoh7, a marker of retinogenesis, is also equivalent in eyes of blm and wildtype siblings. Presented data are average of 3 replicate experiments, each comprising pools of 16-35 larvae. Error bars represent the standard error of the mean (C-D). E) Acridine orange staining of apoptotic cells in wildtype and blm larvae at 24 hpf. Arrows point to regions of increased apoptosis in blm mutants.
Figure 4. top2a, but not top2b, is expressed pre-MZT. RT-PCR of wt embryos (A-B) and real time PCR of offspring from blm carriers (C-D) shows that maternal top2a (A, C), but not top2b (B, D), is present pre-MZT at 8- and 16-cell stages. top2a transcript levels decrease in blm siblings from 27 hpf to 3 dpf, and the expression in blm mutants is always significantly lower (C). The levels of top2b transcript also decrease in wildtype siblings from 27 hpf to 3 dpf, and although top2b levels in blm mutants and siblings is similar at 27 hpf, top2b is dramatically reduced in the mutants by 2 dpf (D). Error bars represent the standard error of the mean. At 8-cell, 16-cell, 4 hpf and 10 hpf stages mutant and wild type offspring are pooled. In graphs light blue (C) and light green bars (D) represent pooled wiltype and mutant embryos; dark blue/green bars represent blm mutants and white bars represent wildtype larvae.
Figure 5. Overlapping expression, but functional divergence of top2a and top2b paralogues in vivo. A) RT-PCR shows that both top2a and top2b are expressed in the eye at 2, 3, 4 and 5 dpf. B-G) Wholemount in situ hybridization reveals that top2b is expressed in the anterior of wildtype larvae including the forebrain, midbrain and eye (B-D) at 22 hpf and in the forebrain, midbrain, branchial arches and retina (F-G) at 3 dpf. E is the negative control sense probe; D and G are sections through the eye. H) RT-PCR at 3 dpf shows similar abundant expression of top2b in the eye and body of blm mutants and wildtype sibling. I-L) Wholemount in situ hybridization reveals a similar spatial expression pattern of top2b in blm (I, K) and wildtype larvae (J, L) at 3 dpf. M) top2b expression levels at 33 hpf following injection of top2b mRNA into 1-2 cell stage offspring of blm carriers. blm larvae overexpressing top2b RNA by 2.7-5.9 fold show no evidence of phenotypic rescue. N = 3 replicate experiments, n = 50 uninjected wild type (wt cont), n = 29 top2b RNA injected wild type (wt inj), n = 13 uninjected blm (blm cont), n = 17 top2b RNA injected blm (blm inj), n = 6 top2b RNA injected malformed. N) Phenotypes recorded at 33 hpf following injecting offspring of carriers of blm mutation with zebrafish top2b mRNA (N ⥠3 replicate experiments, n = 117 uninjected wild type, n = 40 uninjected blm, n = 29 top2b RNA injected wild type, n = 17 top2b RNA injected blm, n = 6 top2b RNA injected malformed). Error bars represent the standard error of the mean. Abbreviations: ba - branchial arches, e - eye, fb - forebrain, hb - hindbrain, ln - lense, mb - midbrain, r - retina.
Figure 6. Chemical inhibition of Top2a pre-MZT does not affect cell cycle profile at 27 hpf. A) Schematic of the experimental procedure. 1-2 cell stage embryos were treated with 100 μM ICRF-193 for 3.5 hours when the drug was removed and the cell cycle profile analysed at 27 hpf. B-C) Flow cytometry analysis of cell cycle profiles of wt (B) and mutant (C) embryos. D) Table documenting the percentage of cells in cell cycle phases following ICRF-193 treatment.
Figure 7. Chemical inhibition of Top2a disrupts pre-MZT development of zebrafish embryos. A) Schematic of the experimental procedure. 1-2 cell stage embryos were treated with Top2a inhibitors for 1.5 hours and their developmental progression was analysed. B-C) Graphs representing the percentage of embryos at a range of developmental stages following treatment with ICRF-193 (B) or etoposide (C). Top2a inhibition changes the staging distribution of embryos which peak at 16-32 cell stage in vehicle controls (DMSO) to peaking at the 8-16 cell stage in drug treated populations. The "unclassified" category includes embryos that do not fit into the standard developmental morphologies, ones in which all cells do not have typical optical transparency, and ones that are malformed. D) Table grouping the percentage of embryos at ⤠16 cell stage or ⥠32 cell stage for each drug treatment. Top2a inhibition increases the number of embryos ⤠16 cell stage by up to 26%, and decreases the number of embryos ⥠32 cell stage by up to 35%. Asterisks represent statistically significant differences (p < 0.005) to DMSO controls.
Figure 8. Inhibition of maternal Top2a in pre-MBT cycling extracts delays cell cycle progression by lengthening the M-phase. A) Cycling extracts from activated Xenopus eggs were treated with 20 μM Top2a inhibitor ICRF-193 diluted in 1% DMSO. To monitor cell cycle progression samples were taken every 10 minutes and phospho-histone H3 expression relative to GAPDH expression plotted. Blue and red bars indicate M phase in DMSO control and ICRF-193 treated extracts, respectively. B) Western blot analysis of phospho-Histone H3 and GAPDH expression levels. C) The increase in M phase length in two different cycling extracts treated with ICRF-193. M phase lengthened on average by 40% (SD = 3.14).
Figure 9. Model depicting how maternal top2a enables pre-MZT development of zebrafish embryos and post-MZT development of top2a mutants.
Aanes,
Zebrafish mRNA sequencing deciphers novelties in transcriptome dynamics during maternal to zygotic transition.
2011, Pubmed
Aanes,
Zebrafish mRNA sequencing deciphers novelties in transcriptome dynamics during maternal to zygotic transition.
2011,
Pubmed
Adachi,
Cell cycle-dependent regulation of the mouse DNA topoisomerase IIalpha gene promoter.
1997,
Pubmed
Akimitsu,
Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase IIalpha.
2003,
Pubmed
Amsterdam,
Identification of 315 genes essential for early zebrafish development.
2004,
Pubmed
Azarova,
Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.
2007,
Pubmed
Bower,
Topoisomerase IIalpha maintains genomic stability through decatenation G(2) checkpoint signaling.
2010,
Pubmed
Capranico,
Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development.
1992,
Pubmed
Carpenter,
Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line.
2004,
Pubmed
Coelho,
Dual role of topoisomerase II in centromere resolution and aurora B activity.
2008,
Pubmed
Costanzo,
An ATR- and Cdc7-dependent DNA damage checkpoint that inhibits initiation of DNA replication.
2003,
Pubmed
,
Xenbase
Cuvier,
A topoisomerase II-dependent mechanism for resetting replicons at the S-M-phase transition.
2008,
Pubmed
,
Xenbase
Cuvier,
A role of topoisomerase II in linking DNA replication to chromosome condensation.
2003,
Pubmed
,
Xenbase
Dovey,
Topoisomerase II alpha is required for embryonic development and liver regeneration in zebrafish.
2009,
Pubmed
Duffy,
Coordinate control of cell cycle regulatory genes in zebrafish development tested by cyclin D1 knockdown with morpholino phosphorodiamidates and hydroxyprolyl-phosphono peptide nucleic acids.
2005,
Pubmed
Etkin,
Regulation of the mid-blastula transition in amphibians.
1988,
Pubmed
,
Xenbase
Haffter,
The identification of genes with unique and essential functions in the development of the zebrafish, Danio rerio.
1996,
Pubmed
Hirano,
Topoisomerase II does not play a scaffolding role in the organization of mitotic chromosomes assembled in Xenopus egg extracts.
1993,
Pubmed
,
Xenbase
Ikegami,
Developmental activation of the capability to undergo checkpoint-induced apoptosis in the early zebrafish embryo.
1999,
Pubmed
,
Xenbase
Ikegami,
Effect of inhibitors of DNA replication on early zebrafish embryos: evidence for coordinate activation of multiple intrinsic cell-cycle checkpoints at the mid-blastula transition.
1997,
Pubmed
Jenkins,
Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24.
1992,
Pubmed
Johnson,
Studying vertebrate topoisomerase 2 function using a conditional knockdown system in DT40 cells.
2009,
Pubmed
Kane,
The zebrafish midblastula transition.
1993,
Pubmed
Kimura,
Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase.
1994,
Pubmed
Li,
Maternal control of early mouse development.
2010,
Pubmed
Linka,
C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo.
2007,
Pubmed
Luo,
Topoisomerase IIalpha controls the decatenation checkpoint.
2009,
Pubmed
Lyu,
Aberrant lamination in the cerebral cortex of mouse embryos lacking DNA topoisomerase IIbeta.
2003,
Pubmed
Lyu,
Role of topoisomerase IIbeta in the expression of developmentally regulated genes.
2006,
Pubmed
Mano,
The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours.
2007,
Pubmed
McClendon,
DNA topoisomerase II, genotoxicity, and cancer.
2007,
Pubmed
McClendon,
Human topoisomerase IIalpha rapidly relaxes positively supercoiled DNA: implications for enzyme action ahead of replication forks.
2005,
Pubmed
Montecucco,
Cellular response to etoposide treatment.
2007,
Pubmed
Murray,
Cell cycle extracts.
1991,
Pubmed
Nevin,
Topoisomerase IIbeta is required for lamina-specific targeting of retinal ganglion cell axons and dendrites.
2011,
Pubmed
Nitiss,
Targeting DNA topoisomerase II in cancer chemotherapy.
2009,
Pubmed
Nitiss,
DNA topoisomerase II and its growing repertoire of biological functions.
2009,
Pubmed
Nur-E-Kamal,
Role of DNA topoisomerase IIbeta in neurite outgrowth.
2007,
Pubmed
Pelegri,
Maternal factors in zebrafish development.
2003,
Pubmed
Roca,
Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp.
1994,
Pubmed
Roca,
Topoisomerase II: a fitted mechanism for the chromatin landscape.
2009,
Pubmed
Sakaguchi,
Functional compatibility between isoform alpha and beta of type II DNA topoisomerase.
2004,
Pubmed
St Pierre,
DNA topoisomerase II is essential for preimplantation mouse development.
2002,
Pubmed
Tadros,
The maternal-to-zygotic transition: a play in two acts.
2009,
Pubmed
Tsutsui,
Involvement of DNA topoisomerase IIbeta in neuronal differentiation.
2001,
Pubmed
Tsutsui,
Immunohistochemical analyses of DNA topoisomerase II isoforms in developing rat cerebellum.
2001,
Pubmed
Woessner,
Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells.
1991,
Pubmed
Yang,
DNA topoisomerase IIbeta and neural development.
2000,
Pubmed